Oncotarget

Clinical Research Papers:

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab

Gerald S. Falchook _, Jennifer J. Wheler, Aung Naing, Edward F. Jackson, Filip Janku, David Hong, Chaan S. Ng, Nizar M. Tannir, Kristie N. Lawhorn, Mei Huang, Laura S. Angelo, Deeksha Vishwamitra, Kenneth Hess, Adrienne N. Howard, Kristin L. Parkhurst, Hesham M. Amin and Razelle Kurzrock

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2014; 5:10280-10292. https://doi.org/10.18632/oncotarget.2163

Metrics: PDF 4473 views  |   HTML 3913 views  |   ?  


Abstract

Gerald S Falchook1, Jennifer J Wheler2, Aung Naing2, Edward F Jackson3, Filip Janku2, David Hong2, Chaan S Ng4, Nizar M Tannir5, Kristie N Lawhorn6, Mei Huang2, Laura S Angelo7, Deeksha Vishwamitra8, Kenneth Hess9, Adrienne N Howard2, Kristin L Parkhurst2, Hesham M Amin8, Razelle Kurzrock10

1Sarah Cannon Research Institute, Denver, CO 80218

2Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, TX 77030

3Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI 53705

4Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030

5Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030

6Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030

7Department of Immunology, Allergy, and Rheumatology, The Center for Human Immunobiology, Texas Children's Hospital/Baylor College of Medicine, Houston, TX 77030

8Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030

9Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030

10Center for Personalized Cancer Therapy, Moores Cancer Center, University of California, San Diego, San Diego, CA 92093

Correspondence to:

Gerald Falchook, e-mail: [email protected]

Keywords: bevacizumab, bortezomib, phase 1, proteasome, HIF-1α

Received: April 29, 2014     Accepted: June 23, 2014     Published: November 08, 2014

ABSTRACT

Purpose: We hypothesized that bortezomib, an agent that suppresses HIF-1α transcriptional activity, when combined with bevacizumab, would obviate the HIF-1α resistance pathway. The objectives of this phase I trial were to assess safety and biological activity of this combination.

Experimental Design: Patients with advanced, refractory malignancies were eligible. Patients received bevacizumab and bortezomib (3-week cycle) with dose expansions permitted if responses were seen and for assessing correlates. Pharmacodynamic assessment included plasma VEGF, VEGFR2, 20S proteasome inhibition, dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and HIF-1α tumor expression.

Results: Ninety-one patients were treated (median=6 prior treatments). The FDA-approved doses of both drugs were safely reached, and the recommended phase 2 dose (RP2D) is bevacizumab 15 mg/kg with bortezomib 1.3 mg/m2. Four patients attained partial response (PR) and seven patients achieved stable disease (SD) ≥6 months (Total SD≥6 months/PR=11 (12%)). The most common drug-related toxicities included thrombocytopenia (23%) and fatigue (19%). DCE-MRI analysis demonstrated no dose-dependent decreases in Ktrans although analysis was limited by small sample size (N=12).

Conclusion: Combination bevacizumab and bortezomib is well-tolerated and has demonstrated clinical activity in patients with previously treated advanced malignancy. Pharmacodynamic assessment suggests that inhibition of angiogenic activity was achieved.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2163